Candriam S.C.A. Apellis Pharmaceuticals, Inc. Transaction History
Candriam S.C.A.
- $15.6 Billion
- Q1 2025
A detailed history of Candriam S.C.A. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 159,054 shares of APLS stock, worth $3.12 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
159,054
Previous 539,602
70.52%
Holding current value
$3.12 Million
Previous $17.2 Million
79.8%
% of portfolio
0.02%
Previous 0.1%
Shares
25 transactions
Others Institutions Holding APLS
# of Institutions
287Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$241 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$239 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$233 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$198 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$189 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.15B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...